Abstract:Apart from their killer identity, natural killer (NK) cells have integral roles in shaping the tumor microenvironment. Through immune gene deconvolution, the present study revealed an interplay between NK cells and myeloid-derived suppressor cells (MDSCs) in nonresponders of immune checkpoint therapy. Given that the mechanisms governing the outcome of NK cell–to–myeloid cell interactions remain largely unknown, we sought to investigate the cross-talk between NK cells and suppressive myeloid cells. Upon contact with tumor-experienced NK cells, monocytes and neutrophils displayed increased expression of MDSC-related suppressive factors along with increased capacities to suppress T cells. These changes were accompanied by impaired antigen presentation by monocytes and increased ER stress response by neutrophils. In a cohort of patients with sarcoma and breast cancer, the production of interleukin-6 (IL-6) by tumor-infiltrating NK cells correlated with S100A8/9 and arginase-1 expression by MDSCs. At the same time, NK cell–derived IL-6 was associated with tumors with higher major histocompatibility complex class I expression, which we further validated with b2m -knockout (KO) tumor mice models. Similarly in syngeneic wild-type and IL-6 KO mouse models, we then demonstrated that the accumulation of MDSCs was influenced by the presence of such regulatory NK cells. Inhibition of the IL-6/signal transducer and activator of transcription 3 (STAT3) axis alleviated suppression of T cell responses, resulting in reduced tumor growth and metastatic dissemination. Together, these results characterize a critical NK cell–mediated mechanism that drives the development of MDSCs during tumor immune escape.

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s

Myeloid-derived Suppressor Cells: Connection Between Inflammation and Cancer

Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8 + T Cells.

Tumoral expression of IL-33 promotes Anti-tumor Immune Responses (TUM2P.912)

Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment Through CD8+ T and NK Cells

Interleukin‐33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage‐Mediated Shedding Mechanism

Myeloid-Derived Suppressor Cells Endow Stem-Like Qualities To Breast Cancer Cells Through Il6/Stat3 And No/Notch Cross-Talk Signaling

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Myeloid-derived suppressor cells in the tumor microenvironment reduce uncoupling protein 1 expression to boost immunosuppressive activity

The IL-33/ST2 Pathway Suppresses Murine Colon Cancer Growth and Metastasis by Upregulating CD40 L Signaling.

Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation

Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis

Myeloid-Derived Suppressor Cells: Roles In The Tumor Microenvironment And Tumor Radiotherapy

Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer

Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy.

MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN.

Microrna-200c Promotes Suppressive Potential Of Myeloid-Derived Suppressor Cells By Modulating Pten And Fog2 Expression